Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Braess

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Deutsche Medizinische Wochenschrift (1946)|November 12, 2016
[Acute myeloid Leukemia]Jan Braess
Medizinische Klinik (Munich, Germany : 1983)|April 12, 2007
[Current therapeutic strategies in the management of acute myeloid leukemia]Michael Fiegl, Wolfgang Hiddemann, Jan Braess
Annals of Hematology|November 2, 2004
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapyMichael Fiegl, Thomas Büchner, Wolfgang Hiddemann, et al.
Leukemia Research|August 31, 2006
Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemiaMichael Fiegl, Matthias Juergens, Wolfgang Hiddemann, et al.
BMJ Open|June 18, 2024
How accurate is clinical prognostication by oncologists during routine practice in a general hospital and can it be improved by a specific prognosis training programme: a prospective interventional studyIrma Kupf, Gabriele Thanner, Michael Gerken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemiaJan Braess, Michael Fiegl, Isolde Lorenz, et al.
Annals of Hematology|August 22, 2007
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemiaMichael Fiegl, Inka Zimmermann, Isolde Lorenz, et al.
Anticancer Research|May 18, 2012
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cellsStefan Holdenrieder, Frank T Kolligs, Jan Braess, et al.
British Journal of Haematology|July 20, 2004
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment responseJan Braess, Peter Schneiderat, Claudia Schoch, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Prognostic parameters and risk stratification in intensive care patients with severe liver diseasesSebastian Lehner, Hans Joachim Stemmler, Alexander Mück, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Deutsche Medizinische Wochenschrift (1946)|November 12, 2016
[Acute myeloid Leukemia]Jan Braess
Medizinische Klinik (Munich, Germany : 1983)|April 12, 2007
[Current therapeutic strategies in the management of acute myeloid leukemia]Michael Fiegl, Wolfgang Hiddemann, Jan Braess
Annals of Hematology|November 2, 2004
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapyMichael Fiegl, Thomas Büchner, Wolfgang Hiddemann, et al.
Leukemia Research|August 31, 2006
Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemiaMichael Fiegl, Matthias Juergens, Wolfgang Hiddemann, et al.
BMJ Open|June 18, 2024
How accurate is clinical prognostication by oncologists during routine practice in a general hospital and can it be improved by a specific prognosis training programme: a prospective interventional studyIrma Kupf, Gabriele Thanner, Michael Gerken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemiaJan Braess, Michael Fiegl, Isolde Lorenz, et al.
Annals of Hematology|August 22, 2007
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemiaMichael Fiegl, Inka Zimmermann, Isolde Lorenz, et al.
Anticancer Research|May 18, 2012
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cellsStefan Holdenrieder, Frank T Kolligs, Jan Braess, et al.
British Journal of Haematology|July 20, 2004
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment responseJan Braess, Peter Schneiderat, Claudia Schoch, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 29, 2010
Prognostic parameters and risk stratification in intensive care patients with severe liver diseasesSebastian Lehner, Hans Joachim Stemmler, Alexander Mück, et al.
Pageof 9